Skip to main content

Table 2 Summary of best overall response

From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

 

mITT population (N = 82)

ORR, n (%)

24 (29.3)

 95% CI

19.7, 40.4

VGPR, n (%)

4 (4.9)

PR, n (%)

20 (24.4)

MR, n (%)

8 (9.8)

SD, n (%)

37 (45.1)

PD, n (%)

7 (8.5)

Not estimable, n (%)

6 (7.3)

  1. ORR, the percentage of patients achieving confirmed best response of sCR, CR, VGPR, or PR
  2. CI Confidence interval, mITT Modified intent-to-treat, MR Minimal response, ORR Overall response rate, PD Progressive disease, PR Partial response, SD Stable disease, VGPR Very good partial response
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us